145 related articles for article (PubMed ID: 29511030)
21. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.
Strumberg D; Schultheis B; Adamietz IA; Christensen O; Buechert M; Kraetzschmar J; Rajagopalan P; Ludwig M; Frost A; Steinbild S; Scheulen ME; Mross K
Br J Cancer; 2008 Nov; 99(10):1579-85. PubMed ID: 19002179
[TBL] [Abstract][Full Text] [Related]
22. Molecularly Confirmed Pseudomyogenic Hemangioendothelioma with Unusual EGFL7::FOSB Fusion in the Head and Neck Region of an Older Patient.
Ren D; Lou J; Wei K; Ifegwu I
Diagnostics (Basel); 2024 Feb; 14(3):. PubMed ID: 38337858
[TBL] [Abstract][Full Text] [Related]
23. Epithelioid hemangioma of bone harboring FOS and FOSB gene rearrangements: A clinicopathologic and molecular study.
Tsuda Y; Suurmeijer AJH; Sung YS; Zhang L; Healey JH; Antonescu CR
Genes Chromosomes Cancer; 2021 Jan; 60(1):17-25. PubMed ID: 33034932
[TBL] [Abstract][Full Text] [Related]
24. FOSB immunoreactivity in endothelia of epithelioid hemangioma (angiolymphoid hyperplasia with eosinophilia).
Ortins-Pina A; Llamas-Velasco M; Turpin S; Soares-de-Almeida L; Filipe P; Kutzner H
J Cutan Pathol; 2018 Jun; 45(6):395-402. PubMed ID: 29527734
[TBL] [Abstract][Full Text] [Related]
25. Pseudomyogenic hemangioendothelioma of skin, bone and soft tissue-a clinicopathological, immunohistochemical, and fluorescence in situ hybridization study.
Pradhan D; Schoedel K; McGough RL; Ranganathan S; Rao UNM
Hum Pathol; 2018 Jan; 71():126-134. PubMed ID: 29104110
[TBL] [Abstract][Full Text] [Related]
26. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
27. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
[TBL] [Abstract][Full Text] [Related]
29. [Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer].
Toffart AC; Sakhri L; Moro-Sibilot D
Rev Pneumol Clin; 2013 Apr; 69(2):111-6. PubMed ID: 23561899
[TBL] [Abstract][Full Text] [Related]
30. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.
Semenisty V; Naroditsky I; Keidar Z; Bar-Sela G
BMC Cancer; 2015 May; 15():402. PubMed ID: 25967676
[TBL] [Abstract][Full Text] [Related]
31. SETDB1-mediated FosB regulation via ERK2 is associated with an increase in cell invasiveness during anticancer drug treatment of A549 human lung cancer cells.
Na HH; Kim KC
Biochem Biophys Res Commun; 2018 Jan; 495(1):512-518. PubMed ID: 29108991
[TBL] [Abstract][Full Text] [Related]
32. Epithelioid hemangioendothelioma of the kidney treated with sunitinib.
Tolkach Y; Petrov S; Lerut E; Van Poppel H
Onkologie; 2012; 35(6):376-8. PubMed ID: 22722460
[TBL] [Abstract][Full Text] [Related]
33. Success is built on failures: tackling the challenge of ponatinib failure.
Hiwase D; Ross D
Leuk Lymphoma; 2018 Jun; 59(6):1279-1281. PubMed ID: 29382246
[No Abstract] [Full Text] [Related]
34. Successful treatment of advanced pancreatic liposarcoma with apatinib: A case report and literature review.
Han T; Luan Y; Xu Y; Yang X; Li J; Liu R; Li Q; Zheng Z
Cancer Biol Ther; 2017 Sep; 18(9):635-639. PubMed ID: 28678611
[TBL] [Abstract][Full Text] [Related]
35. Cabozantinib approved for first-line treatment of advanced renal cell carcinoma.
Clin Adv Hematol Oncol; 2018 Feb; 16(2):96. PubMed ID: 29741507
[No Abstract] [Full Text] [Related]
36. Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment.
Rosenberg A; Agulnik M
Curr Treat Options Oncol; 2018 Mar; 19(4):19. PubMed ID: 29546487
[TBL] [Abstract][Full Text] [Related]
37. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
38. Multicentric visceral epithelioid hemangioendothelioma, with extremity dermal deposits, unusual late recurrence on the nasal bridge, and TFE3 gene rearrangement.
Thway K; Mentzel T; Perrett CM; Calonje E
Hum Pathol; 2018 Feb; 72():153-159. PubMed ID: 28855107
[TBL] [Abstract][Full Text] [Related]
39. Novel GATA6-FOXO1 fusions in a subset of epithelioid hemangioma.
Antonescu CR; Huang SC; Sung YS; Zhang L; Helmke BM; Kirchner M; Stenzinger A; Mechtersheimer G
Mod Pathol; 2021 May; 34(5):934-941. PubMed ID: 33318580
[TBL] [Abstract][Full Text] [Related]
40. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
